|Traded as||NASDAQ: ACOR FWB: CDG|
|Headquarters||Ardsley, New York, United States|
Andrew R. Blight
|Revenue||US$292.2 Million (FY 2011)|
|US$35.1 Million (FY 2011)|
|US$30.6 Million (FY 2011)|
|Total assets||US$379.5 Million (FY 2011)|
|Total equity||US$205.2 Million (FY 2011)|
Number of employees
|328 (February, 2012) |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
As of December 31, 2013[update], the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.